CHRS Stock Analysis: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.45
0.01 (0.69%)
▲
5d:
-2.03%
30d:
-4.61%
90d:
-16.67%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.45, which is considered fair relative to its 30-day fair value range of $1.41 to $1.58.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.39, while resistance sits at $1.56.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.80 (+437.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.39, while resistance sits at $1.56.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.80 (+437.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.41 -
$1.58
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 437.9% below Wall St target ($7.80)
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.58
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.39
Resistance Level
$1.57
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.42
Wall Street Target
$7.80
(+437.9%)
Revenue Growth (YoY)
62.0%
Earnings Growth (YoY)
-75.5%
Profit Margin
397.3%
Share & Embed Analysis
Last updated: July 03, 2026 7:50 PM ET
Data refreshes hourly during market hours. Next update: 8:50 PM
Data refreshes hourly during market hours. Next update: 8:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
